Balanced news tone
News Sentiment
GDTC sentiment intelligence
CytoMed Therapeutics Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
49 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+5.6% over one week, -9.6% over four weeks, trend inactive, and below fair value.
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
5.6%
Price confirming higher
Trend fit
Trend inactive
-9.6% over four weeks
Fair value
-54.4%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
8
Neutral
36
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Moomoo
Direct company coverage
CytoMed Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
This article is a 6-K report from CytoMed Therapeutics, submitted by a foreign private issuer. These reports are related to financial reporting obligations. The content of this particular filing is a document.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 10:10
- Source
- Moomoo
dars.gov.et
Direct company coverage
CytoMed Therapeutics (GDTC) Climbs 5.1% as Shares Approach Resistance at $1.08 - Max Pain Level
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 18:46
- Source
- dars.gov.et
Moomoo
Direct company coverage
CytoMed Therapeutics(GDTC) Stock Options Chain | Quotes & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 16:15
- Source
- Moomoo
Moomoo
Direct company coverage
CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for CytoMed Therapeutics (GDTC). It includes key metrics such as the stock price, market cap, 52-week range, volume, and average volume. The article also touches upon the company's financial performance, analyst price tar
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 10 Jul 2026 16:41
- Source
- Moomoo
TradingView
Direct company coverage
Enterprise value to EBITDA forward of CytoMed Therapeutics Limited – NASDAQ:GDTC
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 04:10
- Source
- TradingView
FinancialContent
Direct company coverage
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
CytoMed Therapeutics Ltd (NASDAQ: GDTC), a clinical-stage biotech company, is making strides in developing affordable cancer therapies using patented allogeneic Gamma Delta T Cells. The company is currently conducting clinical trials in Singapore and plans to expand to Malaysia,
- Tone
- Positive 77/100
- Event
- Market update
- Published
- 09 Jul 2026 18:39
- Source
- FinancialContent
Finviz
Direct company coverage
GDTC - CytoMed Therapeutics Ltd Options
This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its last close price, market capitalization, income, sales, key financial ratios, and stock performance metrics. It lists various operational and financial indicators, such as ROA, R
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 16:09
- Source
- Finviz
Finviz
Direct company coverage
GDTC - CytoMed Therapeutics Ltd Volatility & Greeks
This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's volatility and various financial ratios, offering a snapsho
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 03 Jul 2026 18:40
- Source
- Finviz
The Globe and Mail
Direct company coverage
CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank
CytoMed Therapeutics chairman, Choo Chee Kong, is increasing his personal stake in the company by acquiring up to 200,000 shares and also invested S$300,000 in CytoMed’s subsidiary, LongevityBank Pte Ltd, through his wholly owned EP Capital Inc. This investment will double EP Cap
- Tone
- Positive 67/100
- Event
- Deals and strategy
- Published
- 27 Jun 2026 16:09
- Source
- The Globe and Mail
TradingView
Direct company coverage
CytoMed Therapeutics Limited Actuals & Estimates (NASDAQ:GDTC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 05:09
- Source
- TradingView
Investing.com
Direct company coverage
Form 6K CytoMed Therapeutics Ltd For: 23 June
This article announces the filing of Form 6K by CytoMed Therapeutics Ltd for June 23. It includes disclaimers about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate and that investors should be f
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 22:10
- Source
- Investing.com
Investing.com Nigeria
Direct company coverage
Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com
This article provides details of a Form 6K filing by CytoMed Therapeutics Ltd for June 23. The content is brief, primarily serving as a notification of the filing, and includes general financial market data such as indices, commodities, bonds, and shares, which are not directly r
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 17:24
- Source
- Investing.com Nigeria
Stock Titan
Direct company coverage
CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D
CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, plans to acquire up to 200,000 company shares through private cash transactions, demonstrating increased personal exposure to the stock. Separately, his entity, EP Capital Inc., invested S$300,000 (approximately US$250,
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 23 Jun 2026 16:10
- Source
- Stock Titan
dars.gov.et
Direct company coverage
CytoMed Therapeutics (GDTC) Holds Flat at $1.09 as Trading Range Narrows - Synthetic Long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- dars.gov.et
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), focusing on support, resistance, indicators, and moving averages. It synthesizes various technical indicators like MACD, RSI, and MA to offer a comprehensive outlook. The analysis indicates a "Sell" si
- Tone
- Negative 38/100
- Event
- Guidance
- Published
- 18 Jun 2026 08:11
- Source
- TradingKey
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis
This article provides an analysis of CytoMed Therapeutics Ltd (GDTC) valuation metrics, specifically Price-to-Earnings (P/E), Price-to-Book (P/B), and Fair Value. It explicitly states that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The p
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:39
- Source
- TradingKey
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), focusing on future EPS and revenue growth estimates. It notes that relevant data has not yet been disclosed by the company, thus no forecast figures are available. However, analysts forecast a price t
- Tone
- Positive 61/100
- Event
- Earnings
- Published
- 18 Jun 2026 06:08
- Source
- TradingKey
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Institutional Confidence
This article provides details on the institutional confidence in CytoMed Therapeutics Ltd (GDTC), including its stock performance, market capitalization, and key institutional shareholders. It lists several institutional investors and individual shareholders, along with their sha
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 06:08
- Source
- TradingKey
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for CytoMed Therapeutics Ltd (GDTC), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Sharpe Ratio, a
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 18 Jun 2026 03:40
- Source
- TradingKey
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of CytoMed Therapeutics Ltd's (GDTC) shareholder structure, detailing major shareholders and institutional holdings. It lists the proportion held by key entities like Glorious Finance Limited and mDR Limited, alongside a breakdown by shareholder
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 20:40
- Source
- TradingKey
TradingKey
Direct company coverage
CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for CytoMed Therapeutics Ltd (GDTC), focusing on its business segments, regional revenue, and profit contribution. It states that relevant data for these categories have not yet been disclosed by the company. The page also includes current
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 20:40
- Source
- TradingKey
Stock Titan
Direct company coverage
CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market
CytoMed Therapeutics director and ten percent owner Choo Chee Kong purchased 112,000 Ordinary Shares in an open-market transaction at $1.1498 per share, totaling $128,778. Following this acquisition, Choo Chee Kong directly owns 430,324 Ordinary Shares. The filing indicates a pos
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 15 Jun 2026 10:40
- Source
- Stock Titan
Quiver Quantitative
Direct company coverage
Insider Purchase: Director at $GDTC Buys 112,000 Shares | GDTC Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Quiver Quantitative
Simply Wall Street
Direct company coverage
CytoMed Therapeutics (Nasdaq:GDTC) - Stock Analysis
This article provides a stock analysis of CytoMed Therapeutics (Nasdaq:GDTC), highlighting its status as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies. It details the company's financial performance, including declining earnings and an undervalu
- Tone
- Negative 38/100
- Event
- Earnings
- Published
- 05 Jun 2026 02:09
- Source
- Simply Wall Street
Stock Titan
Direct company coverage
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals
CytoMed Therapeutics (NASDAQ: GDTC) shareholders approved all ten proposals at its Annual General Meeting (AGM) held on May 22, 2026, in Singapore. These approvals included adopting financial statements, re-electing directors Dr. Yew Chak Hua and Dr. Toh Keng Kiat, waiving the Si
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 19:40
- Source
- Stock Titan
dars.gov.et
Direct company coverage
CytoMed Therapeutics (GDTC) Dips 2.48% as Key Support at $1.08 Comes into Focus - Volume Dry Up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- dars.gov.et
Finviz
Direct company coverage
GDTC - CytoMed Therapeutics Ltd Stock Price and Quote
This article provides a detailed stock price and quote for CytoMed Therapeutics Ltd (GDTC), including its last closing price, financial metrics, and recent news. It highlights various financial data points like market cap, income, sales, and insider ownership, alongside a chronol
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 01 Jun 2026 00:14
- Source
- Finviz
Stock Titan
Direct company coverage
CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares
CytoMed Therapeutics director Toh Keng Kiat has reported an initial beneficial ownership of 4,000 Ordinary Shares in the company. This disclosure is a routine Form 3 filing with the SEC and signifies an existing holding rather than a new transaction. The shares are directly owned
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 12:40
- Source
- Stock Titan
openPR.com
Direct company coverage
CytoMed Therapeutics Ltd - A Rising Star in Singapore's Cancer Biotechnology Sector
CytoMed Therapeutics Ltd, a clinical-stage biotech company based in Singapore, is making significant strides in developing affordable cancer therapies using allogeneic Gamma Delta T Cells. Through strategic acquisitions and a focus on global expansion, particularly in China and I
- Tone
- Positive 65/100
- Event
- Deals and strategy
- Published
- 21 May 2026 10:40
- Source
- openPR.com